Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

15 novembre 2017

09:00
An especially aggressive breast cancer cell can respond to hormone therapy if they express a specific protein known as estrogen receptor beta (ER?), according to new research published on the cover of Oncotarget. The findings also revealed additional...

09:00
Promius Pharma LLC announced today that ZEMBRACE® SymTouch® (sumatriptan injection) 3 mg, an acute migraine headache treatment on the market since April 2016, achieved its primary and multiple secondary endpoints in a 268-subject, post-approval...

08:40
Genisphere LLC announced positive results from a non-GLP safety study evaluating dose escalation and repeated dose toxicity of the company's 3DNA nanocarrier in Sprague Dawley rats. The study demonstrated no adverse clinical findings after repeated...

08:30
Ampio Pharmaceuticals, Inc. announced the beginning of an Open Label Extension (OLE) study of Ampiontm in patients with severe osteoarthritis of the knee (OAK). The OLE study offers patients an opportunity to receive repeat injections of Ampiontm...

08:30
PharmaMar (MCE:PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has notified the Company of its recommendation that the Phase III (ATLANTIS) trial currently under way with Zepsyre® (PM1183) in combination with...

08:05
Cingulate Therapeutics, LLC, a clinical stage biopharmaceutical company focused on the development of new and innovative products utilizing an innovative drug delivery platform technology, today announced the presentation of a poster titled,...

08:00
Janssen Inc. a annoncé aujourd'hui que Santé Canada a approuvé TREMFYAtm (guselkumab) pour le traitement du psoriasis en plaques modéré à grave chez les adultes qui sont candidats à un traitement systémique ou à une photothérapie1. TREMFYAtm est le...

08:00
Eidos Therapeutics, a subsidiary of BridgeBio Pharma, today announced that recently presented preclinical data highlight the potential of AG10 to treat TTR amyloid cardiomyopathy (ATTR-CM). These data were shared publicly for the first time yesterday...

08:00
Janssen Inc. announced today that Health Canada has approved TREMFYAtm (guselkumab) for the treatment of adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.1 TREMFYAtm is the first approved...

05:00
Outpost Medicine, a biopharmaceutical company focused on the development of new treatments of urologic and gastrointestinal disorders, today announced the appointment of Scott Byrd as President and Chief Executive Officer as part of a planned...

03:30
NeuroVive Pharmaceutical AB today announced that the company will present data from its clinical phase IIa study on traumatic brain injury (TBI), Copenhagen Head Injury Ciclosporin Study (CHIC), at the Nordic Neurotrauma Conference (NNC) in Lund,...

01:10
Sangamo Therapeutics, Inc. today announced treatment of the first patient in the Phase 1/2 clinical trial ("the CHAMPIONS study") evaluating SB-913, an investigational in vivo genome editing therapy for people with mucopolysaccharidosis type II (MPS...


14 novembre 2017

18:02
Biohaven Pharmaceutical Holding Company Ltd. , a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders, today reported financial results for...

17:08
Studies of three deadly infections in cats are among the research projects awarded more than $400,000 in grants from Morris Animal Foundation, the organization announced today. The studies will help veterinary scientists advance the health of cats,...

16:17
QIAGEN N.V. today announced new studies highlighting the outstanding analytical performance and ease of use of the GeneReader NGS System, the world's first complete Sample to Insight solution for next-generation sequencing. The studies are being...

14:59
For childhood cancers, clinical trials are not the exception; they are the standard of care, with each patient receiving either the best-known treatment or one that may prove to be better. To allow more kids access to clinical trials, the St....

13:34
Neurocrine Biosciences, Inc. announced today that the full manuscript of the long-term safety and efficacy data from the blinded KINECT 3 Phase III extension study evaluating INGREZZA® (valbenazine) capsules for the treatment of adults with tardive...

13:30
A world-first clinical trial delivered by the Royal College of Surgeons in Ireland, on behalf of farming and food company Devenish, has proven that the regular consumption of naturally enriched omega-3 chicken and eggs is likely to reduce risk of...

13:24
The Muscular Dystrophy Association today announced 13 new research and development grants totaling $3.5 million to accelerate the development of treatments for muscular dystrophy, ALS and related life-threatening diseases. With the addition of these...

12:05
With opioid addiction officially declared a public health emergency in the U.S., medical intervention to treat the illness is increasingly important in responding to the epidemic. Now, a new study concludes that two of the top medications available...

11:30
Results from two early clinical trials show that it may be possible to use human embryonic stem cells as treatment for the dry form of macular degeneration, according to presentations given today at AAO 2017, the 121st Annual Meeting of the American...

11:00
Polydactyly, or having an extra finger, is fairly common, occurring in 1 in every 1,000 people?among African-Americans, 1 in 150. Children with supernumerary digits are usually treated within the first months of infancy. According to a case report...

08:36
Global Gene Corp today announced a collaboration with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James), Department of Radiation Oncology, to develop a...

08:22
Le New England Journal of Medicine a publié les résultats de l'étude DAWN, la première étude à fournir des preuves convaincantes concernant le traitement des victimes d'AVC tardif et du réveil par une thrombectomie mécanique. Actuellement, moins d'un...

08:00
Allergan, Inc. , in partnership with the National Association For Continence (NAFC), today announced the results of a new survey that revealed the impact of overactive bladder (OAB) and related symptoms on those living with the condition, as well as...

08:00
Oramed Pharmaceuticals Inc. (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Israel's Ministry of Health has granted the Company approval to initiate an...

08:00
Daiichi...

08:00
Citius Pharmaceuticals, Inc. ("Citius") ("Company") , a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, noted that a recent paper presented at the Infectious Disease Society of America (IDSA)...

08:00
Advances in next-generation sequencing (NGS) have revolutionized the use of genetic information to improve the understanding of cancer and how the disease can be addressed through precision medicine. In pursuit of this endeavor, Thermo Fisher...

08:00
Janssen Research & Development, LLC (Janssen) today announced a new analysis from the CANVAS Program, which showed INVOKANA® (canagliflozin) demonstrated a reduced risk of cardiovascular (CV) outcomes in patients with and without a history of CV...

08:00
Oracle Health Sciences today announced that it has been identified as a Leader in the top quartile in Everest Group's PEAK Matrixtm Assessment of Life Sciences Clinical Trial Products 2017. Oracle Health Sciences...

07:33
Replimune Group Inc., a biotechnology company developing next generation oncolytic immunotherapies, announced today that the first cohort of patients has been dosed in a phase 1/2 clinical trial of RP1 in patients with advanced solid tumors. RP1 is...

07:15
Novartis will present data across its breast cancer portfolio and pipeline in a broad range of patient populations, treatment combinations and pathways at the upcoming 40th annual San Antonio Breast Cancer Symposium (SABCS), San Antonio, December...

07:04
Corvia Medical, Inc., a privately-held medical device company that developed a first-in-class transcatheter structural heart device to treat heart failure, today announced that it has enrolled the first patients in its global multicenter trial...

07:00
Bayer announced today that the company has entered into an exclusive global collaboration with Loxo Oncology, Inc., a biopharmaceutical company based in Stamford, Connecticut for the development and commercialization of larotrectinib (LOXO-101) and...

06:30
TapImmune Inc. , a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced that it has enrolled the final patient in a randomized Phase 2 clinical study of its novel T-cell vaccine...

05:30
Achieve Life Sciences, Inc. , a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced results of a clinical study evaluating the effect of food on the...

03:30
GENOMICA, a leading molecular diagnostics company belonging to the PharmaMar Group (MCE: PHM), has announced that it has received authorization in South Korea for commercializing CLART® in vitro diagnostic kits together with the autoclart® plus...

03:00
Debiopharm International SA (Debiopharm - http://www.debiopharm.com), part of Debiopharm Grouptm, a Swiss-based global biopharmaceutical company, today announced that the European Medicines Agency (EMA) granted Orphan Drug Designation to Debio 1347...

03:00
Two year study* found that clinicians' use of Azurion enabled significant reductions in procedure time, in-lab patient preparation time, post-procedure lab time and enhanced staff experience  Improvements correspond to the ability to treat...

01:30
GENOMICA, une société de diagnostic moléculaire de premier plan du groupe PharmaMar (MCE : PHM), a annoncé avoir reçu l'autorisation des autorités sanitaires compétentes pour la commercialisation des kits de diagnostic in vitro CLART® ainsi que des...


13 novembre 2017

20:30
Boehringer Ingelheim today announced results from two new analyses of the phase III RE-VERSE ADtm study, which evaluated the safety and efficacy of idarucizumab, marketed in the U.S. as Praxbind®, in reversing the anticoagulant effect of Pradaxa®...

20:02
Le New England Journal of Medicine a publié les résultats de l'étude clinique DAWN, la première à fournir des preuves convaincantes de l'utilisation d'une thrombectomie mécanique pour traiter les victimes d'accident vasculaire cérébral de stade...

18:45
New data presented today showed that Jardiance® reduced the risk of cardiovascular death compared with placebo when added to standard of care in adults with type 2 diabetes and peripheral artery disease. These results, from a post-hoc analysis of the...

17:00
A study of two medications that can reduce risk of ischemic stroke in people with atrial fibrillation showed that outcomes in typical patients with atrial fibrillation align well with those seen in clinical trials. The findings are being published...

16:15
Mirati Therapeutics, Inc. (the Company or Mirati), a clinical-stage targeted oncology company, today announced that it is reprioritizing its development programs to capitalize on encouraging data and development opportunities in its sitravatinib and...

16:05
Myovant Sciences , a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced corporate updates and reported financial results for the second...

16:00
Amgen today announced five new subgroup analyses from the Repatha® (evolocumab) cardiovascular outcomes study (FOURIER) that showed the addition of Repatha to statin therapy improved clinical outcomes with significant reduction of cardiovascular...

15:02
Most people know about the effects of smoking on the lungs, but did you know that smoking is also a leading risk factor for the development of bladder cancer and other bladder conditions such as urinary incontinence and painful bladder...

15:00
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it will present its Residue-Specific Conjugation Technology (RESPECT) at the 9th Annual Protein & Antibody Engineering Summit (PEGS) Europe being held November 13-17 at Epic Sana...

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18